Related Experiment Videos
Tumour necrosis factor and inflammatory bowel disease
A M Armstrong1, K R Gardiner, S J Kirk
1Department of Surgery, Queen's University of Belfast, Institute of Clinical Science, UK.
The British Journal of Surgery
|August 1, 1997
Summary
Tumour necrosis factor (TNF) plays a role in inflammatory bowel disease. While anti-TNF antibodies may help acute flares, they are not ideal for long-term treatment of this condition.
Area of Science:
- Immunology
- Gastroenterology
Background:
- Tumour necrosis factor (TNF) is a key cytokine involved in inflammatory processes.
- TNF is produced by macrophages and T lymphocytes and implicated in various immunoinflammatory diseases.
- Emerging research suggests anti-TNF antibodies show potential for treating inflammatory bowel disease (IBD).
Purpose of the Study:
- To review the role of TNF in the pathogenesis of IBD.
- To evaluate the efficacy and implications of TNF inhibitors in IBD treatment.
Main Methods:
- Literature review of studies on TNF's role in IBD.
- Analysis of published results concerning TNF inhibitors in IBD patients.
Main Results:
- TNF is implicated in the development of inflammatory bowel disease.
- The mechanisms and outcomes of TNF inhibitor therapies are complex and not fully understood.
- Anti-TNF antibodies show promise for managing acute exacerbations of IBD.
Conclusions:
- TNF is a significant factor in IBD pathogenesis.
- TNF inhibitors have complex and not fully elucidated effects.
- Anti-TNF antibody therapy may be beneficial for acute IBD flares but not for sustained management.